- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
The company will showcase data on Plinabulin's ability to boost the efficacy of antibody-drug conjugates in cancer treatment.
Mar. 30, 2026 at 11:53am
Got story updates? Submit your updates here. ›
BeyondSpring Inc., a clinical-stage biopharmaceutical company, announced that it will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California. The presentation will focus on data showing that Plinabulin, BeyondSpring's lead asset, can boost the antitumor efficacy of topoisomerase inhibitor-based antibody-drug conjugates, both with and without immune checkpoint inhibitors.
Why it matters
As a novel dendritic cell maturation agent, Plinabulin has the potential to restore tumor sensitivity to checkpoint inhibitors, offering a unique approach to cancer treatment. The data being presented at AACR could further demonstrate Plinabulin's versatility and therapeutic potential when combined with other cancer therapies.
The details
The poster presentation, titled "Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor," will be presented by a team of BeyondSpring researchers, including Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, and Lan Huang. The presentation will take place on April 21, 2026, from 2 PM to 5 PM PT, in Poster Section 8 at the San Diego Convention Center.
- The AACR Annual Meeting 2026 will take place from April 17 through 22, 2026 in San Diego, California.
- BeyondSpring's poster presentation will be on April 21, 2026, from 2 PM to 5 PM PT.
The players
BeyondSpring Inc.
A clinical-stage biopharmaceutical company developing transformative therapies for the treatment of cancer and other diseases, with Plinabulin as its lead asset.
American Association for Cancer Research (AACR)
A professional organization dedicated to advancing cancer research and discovery, hosting the annual AACR meeting.
Yingjuan June Lu
A researcher at BeyondSpring and one of the presenters of the poster.
Xiaoyan He
A researcher at BeyondSpring and one of the presenters of the poster.
Weiwei Cheng
A researcher at BeyondSpring and one of the presenters of the poster.
What they’re saying
“Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor”
— Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, Lan Huang, Presenters
What’s next
The data presented at the AACR Annual Meeting 2026 could lead to further research and development of Plinabulin in combination with antibody-drug conjugates and immune checkpoint inhibitors for the treatment of cancer.
The takeaway
BeyondSpring's presentation at the AACR Annual Meeting showcases the versatility of its lead asset, Plinabulin, and its potential to enhance the efficacy of other cancer therapies, offering a unique approach to restoring tumor sensitivity and improving patient outcomes.
